Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Minish Jain"'
Autor:
Manjunath Krishnappa, Divyesh Mandavia, Minish Jain, Mukesh S, Ankit Patel, Anshul Agarwal, Sanjeev Giri, Nirbhay Kumar Tiwari, Saravanan Thiyagarajan, Mamon Dey, Gutta Padmanabha Naidu, Murali Ramachandra, Akhil Kumar
Publikováno v:
HemaSphere, Vol 7, p e183727f (2023)
Externí odkaz:
https://doaj.org/article/6ad1547013ca44a2b06e4f4eb555b075
Autor:
Shubhadeep D Sinha, Ghanashyam Biswas, Bala Reddy Bheemareddy, Sreenivasa Chary, Pankaj Thakur, Minish Jain, Tanveer Maksud, Suraj Pawar, Koushik Chatterjee, Murali Krishna Voonna, Anil Goel, Krishna Chaitanya Puligundla, Kuntegowdanahalli Chinnagiriyappa Lakshmaiah, Leela Talluri, Ramya Vattipalli, Sheejith Kakkunnath
Publikováno v:
Cancer Informatics, Vol 22 (2023)
Objective: The aim of this study was to evaluate the post-marketing safety, tolerability, immunogenicity and efficacy of Bevacizumab (manufactured by Hetero Biopharma) in a broader population of patients with solid tumors. Patients And Methods: This
Externí odkaz:
https://doaj.org/article/25def5a4029d43afa85aaee5274c5cf2
Autor:
Minish Jain, Sharad Desai, Rajnish Nagarkar, Rakesh Neve, Unmesh Takalkar, Dhananjay Bakhle, Chirag Shah
Publikováno v:
Journal of Clinical and Diagnostic Research, Vol 16, Iss 8, Pp XC01-XC07 (2022)
Introduction: Pegfilgrastim is indicated in patients receiving myelosuppressive anticancer drugs to reduce the Duration of Severe Neutropenia (DSN) and incidence of Febrile Neutropenia (FN). The efficacy and safety of a proposed Pegfilgrastim biosimi
Externí odkaz:
https://doaj.org/article/9b55a14751e540a387707e2304f95a66
Autor:
Chaitanya Kumar, Jasmine Bagga, Srikanth Chiliveru, Sakshi Kohli, Asmi Bharadwaj, Minish Jain, Shriram Inamdar, Bandana Sharan
Publikováno v:
Future Science OA, Vol 5, Iss 10 (2019)
Of the most prevalent solid tumors with advanced disease, prostate and ovarian cancer and non-small cell lung carcinoma have the fewest therapeutic options. Herein, we report the case of a 63-year-old male with metastatic prostate adenocarcinoma show
Externí odkaz:
https://doaj.org/article/3b2cbe4a66e74825bf8562d54b9e9f87
Autor:
Ankit Patel, Niraj Bhatt, S. S. Prakash, Ghanashyam Biswas, Rajnish Nagarkar, Bodhisatta Roy, Priyanka Samal, Narendra Agrawal, Sushil Meshram, Ashish Kaushal, C. T. Satheesh, Ravikumar Wategaonkar, Kasi Viswanathan Thiagarajan, Kartikeya Jain, P. Vijayaveeran, Kalyan Mukherjee, Kishore Singh, Tushar Patil, Amit Jain, Tuphan Kanti Dolai, Minish Jain, Sachin Hingmire, Tara Chand Gupta, K. C. Lakshmaiah, Deepan Rajamanickam, Bhushan Nemade, Vikash Goyal, Pinaki Mahato, Sanjeev Kumar Mendiratta, Maulik Doshi
Publikováno v:
Cancer Chemotherapy and Pharmacology. 91:457-468
Autor:
Ketaki Patil, T Raja, Rahul Sud, Sanjai Addla, KalyanK Sarkar, PS Sridhar, Vikas Talreja, Minish Jain
Publikováno v:
Indian journal of cancer. 59
Androgen deprivation therapy (ADT) using gonadotropin-releasing hormone agonist (s) (GnRH-A) remains the backbone of advanced prostate cancer treatment. In this review, we assessed the efficacy, safety, and convenience of administration of various Gn
Publikováno v:
Indian journal of cancer. 58(2)
We herein describe a case of primary leiomyosarcoma of descending mesocolon mesentery in a pregnant woman. A 31-year-old woman was referred to our clinic for the presence of a suspicious mass (solid heterogenous lesion with lobulated margins) detecte
Autor:
Chaitanya, Kumar, Sakshi, Kohli, Srikanth, Chiliveru, Poonamalle Parthasarathy, Bapsy, Minish, Jain, Venkata Sathya, Suresh Attili, Jagan, Mohan, Ashok K, Vaid, Bandana, Sharan
Publikováno v:
Immunotherapy. 9(11)
A retrospective survival benefit analysis of APCEDENSubjects (retrospective data) whose survival data, geographical region, age, gender, ECOG performance status and stage of disease that could be matched with the treatment group were considered for a
Autor:
M. Schuler, J.C.-H. Yang, K. Park, J.-H. Kim, J. Bennouna, Y.-M. Chen, C. Chouaid, F. De Marinis, J.-F. Feng, F. Grossi, D.-W. Kim, X. Liu, S. Lu, J. Strausz, Y. Vinnyk, R. Wiewrodt, C. Zhou, B. Wang, V.K. Chand, D. Planchard, SaiHong Ignatius Ou, David Planchard, Keunchil Park, Martin Schuler, James Yang, Vikram Chand, Klaus Rohr, Claudia Bagnes, Claudio Marcelo Martin, Gonzalo Recondo, Juan Jose Zarba, Cesar Blajman, Martín Richardet, Sue-Anne McLachlan, Phillip Parente, Craig Underhill, Catherine Crombie, Paul Mainwaring, Richard Greil, Yves Humblet, Frédérique Bustin, Luciano Carestia, Danny Galdermans, Marc Lambrechts, Laetitia Delval, Piet Vercauter, Caicun Zhou, Jin Wang, Cheng Huang, Xiaoyan Lin, Yilong Wu, Xiaoqing Liu, Ying Cheng, Shukui Qin, Jifeng Feng, Jianjin Huang, Yiping Zhang, Shun Lu, Manuela Zereu, Bernardo Garicochea, Cyntia Albuquerque Zadra, Henrik Riska, Tuomo Alanko, Jacques Cadranel, Christos Chouaid, Gérard Zalcman, Denis Moro Sibilot, Maurice Perol, Jaafar Bennouna, Pierre Fournel, Radj Gervais, Maciej Rotarski, Bruno Coudert, Michael Thomas, Thomas Wehler, Martin Faehling, Ulrich Keilholz, Eckart Laack, Joachim von Pawel, Rudolf Huber, Nicolas Dickgreber, Rainer Wiewrodt, Zsuzsanna Mark, Sandor Tehenes, Janos Strausz, Veronika Sarosi, Kumar Prabhash, Minish Jain, Srinivasan Venkatesan, Lalit Sharma, Hemant Dadhich, Rajnish Vasant Nagarkar, Amir Onn, Maya Gottfried, Solomon Stemmer, Maria Rita Migliorino, Francesco Grossi, Paolo Bidoli, Alessandra Bearz, Cesare Gridelli, Carlo Milandri, Marco Platania, Giovanni Luca Ceresoli, Giorgio Cruciani, Francisco Gutierrez Delgado, José Luis Gonzalez Perez, Gabriela Alvarado Luna, Othon Padilla Baca, J.G.J.V. Aerts, J.A. Stigt, A.M.C. Dingemans, G.J.M. Herder, S.J.M. Gans, Jorge Fernando Salas Sánchez, Renzo Luzgardo Alvarez Barreda, Wilbert Rodriguez Pantigoso, Osbert Luis Mejia Palomino, Piotr Jaskiewicz, Andrzej Kazarnowicz, Piotr Serwatowski, Aleksandra Szczesna, Jacek Jassem, Vladimir Lubennikov, Nina Karaseva, Sergey Orlov, Yuri Ragulin, Pilar Garrido, José Luis González Larriba, Carlos Camps, Rosario García Campelo, Pilar Lianes, Manuel Cobo, Enriqueta Felip, Dong-Wan Kim, Sang-We Kim, Joo-Hang Kim, Ji-Youn Han, Young-Chul Kim, Chih-Hsin Yang, Te-Chun Hsia, Yuh-Min Chen, Ying-Huang Tsai, Gee-Chen Chang, Thomas Chang-Yao Tsao, Wu-Chou Su, Ming-Shyan Huang, Ching-Liang Ho, Ruey-Kuen Hsieh, Yuriy Vinnyk, Oleksandr Popovych, Olga Ponomarova, Igor Bondarenko, Iryna Polishchuk, Riyaz Shah, Sanka Mitra, Sanjaykumar Popat, James Spicer, Elizabeth Toy, Toby Talbot, Emma Brown, Sunil Upadhyay, Yvonne Summers, Jayne Gurtler, Luis Meza, John Thropay
Background: Afatinib has demonstrated clinical benefit in patients with non-small-cell lung cancer progressing after treatment with erlotinib/gefitinib. This phase III trial prospectively assessed whether continued irreversible ErbB-family blockade w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf515edf6f94f014c68f3cf563cb2ea0
http://hdl.handle.net/11383/2118727
http://hdl.handle.net/11383/2118727
Autor:
Kamil Kaplanov, Andrey Zaritskiy, Sergey Alexeev, Elena Volodicheva, Alexander Loginov, Rashida Orlova, Victoria Dvornichenko, Marina Kosinova, Olga Serduk, Vladimir Milovanov, Alexander Myasnikov, Shekar Patil, Bharath Rangarajan, Senthil Jagannathan Rajappa, Minish Jain, Sharanabasappa Nirni, Akhil Deka, Grigoriy B Rekhtman, Iryna Kryachok, Zvenyslava Maslyak, Ekaterina Chernyaeva, Roman Ivanov, Alexander Isaev
Publikováno v:
Blood. 124:5467-5467
BCD-020 (Acellbia, rituximab biosimilar candidate) was shown to be highly similar to innovator rituximab (MabThera®/Rituxan®) in terms of its quality characteristics, in vitro biological activity, as well as toxicology and PK/PD characteristics in